Liver transplantation as a treatment option for end-stage liver diseases is associated with a relevant risk for complications. On the one hand, immunological factors and associated chronic graft rejection are major causes of morbidity and carry an increased risk of mortality due to liver graft failure. On the other hand, infectious complications have a major impact on patient outcomes. In addition, abdominal or pulmonary infections, and biliary complications, including cholangitis, are common complications in patients after liver transplantation and can also be associated with a risk for mortality. Thereby, these patients already suffer from gut dysbiosis at the time of liver transplantation due to their severe underlying disease, causing end-stage liver failure. Despite an impaired gut-liver axis, repeated antibiotic therapies can cause major changes in the gut microbiome. Due to repeated biliary interventions, the biliary tract is often colonized by several bacteria with a high risk for multi-drug resistant germs causing local and systemic infections before and after liver transplantation. Growing evidence about the role of gut microbiota in the perioperative course and their impact on patient outcomes in liver transplantation is available. However, data about biliary microbiota and their impact on infectious and biliary complications are still sparse. In this comprehensive review, we compile the current evidence for the role of microbiome research in liver transplantation with a focus on biliary complications and infections due to multi-drug resistant germs.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10003075 | PMC |
http://dx.doi.org/10.3390/ijms24054841 | DOI Listing |
J Transl Med
January 2025
Maimonides Biomedical Research Institute of Cordoba (IMIBIC), University of Cordoba, Cordoba, Spain.
Background: Transarterial chemoembolization (TACE) is the first-line therapeutic option for patients with intermediate-stage hepatocellular carcinoma (HCC). Tumor neovascularization allows tumor growth and may facilitate the release of circulating tumor cells (CTCs) to the bloodstream after TACE. We investigated the relationship between early release of CTCs and radiological response after TACE.
View Article and Find Full Text PDFBMC Surg
January 2025
Department of Anesthesiology and Intensive Care and Pain Medicine, Faculty of Medicine, Mansoura University, Mansoura, Egypt.
Background: To investigate the incidence and potential predictors of immune tolerance among adult living donor liver transplant (LDLT) recipients.
Methods: This case-control study included adult recipients who underwent LDLT between May 2004 and January 2018, with at least a 5-year follow-up after LDLT. We divided the study recipients into two groups: Group 1 (Tolerance Group) included recipients who achieved operational or prope tolerance for at least one year; Group 2 (Control Group) included recipients who did not achieve tolerance.
BMC Infect Dis
January 2025
Botany and Microbiology Department, Faculty of Science, Menoufia University, Shebeen El-Kom, Egypt.
Background: Liver transplantation (LT) is a critical intervention for individuals with end-stage liver disease; yet, post-transplant problems, especially infections, graft rejection, and chronic liver disease, are often linked to systemic inflammation. Cytokines, small signaling molecules, significantly influence immune responses during and post-liver transplantation. Nonetheless, the intricate relationships among cytokines, immune responses, and the gut microbiota, especially gut dysbiosis, are still inadequately comprehended.
View Article and Find Full Text PDFCell Mol Biol Lett
January 2025
Clinical Research Center, Jiading District Central Hospital Affiliated to Shanghai University of Medicine and Health Sciences, Shanghai, 201800, China.
Background: Circular (circ)RNAs have emerged as crucial contributors to cancer progression. Nonetheless, the expression regulation, biological functions, and underlying mechanisms of circRNAs in mediating hepatocellular carcinoma (HCC) progression remain insufficiently elucidated.
Methods: We identified circUCK2(2,3) through circRNA sequencing, RT-PCR, and Sanger sequencing.
J Vasc Interv Radiol
January 2025
Inonu University, Faculty of Medicine, Department of Biostatistics and Medical Informatics, Malatya, Türkiye.
Purpose: To evaluate changes in non-target hepatic hemangiomas, which are neither subjected to embolization nor targeted for treatment, following selective bleomycin-lipiodol transarterial chemoembolization (TACE) of a giant hepatic hemangioma.
Materials And Methods: This single-center retrospective study included 24 patients with non-target hepatic hemangiomas distinct from primary giant hemangiomas treated with selective bleomycin-lipiodol TACE between 2009 and 2022. The size and volume of the lesions were assessed using computed tomography scans obtained before treatment, and at 6, 12 and 24 months.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!